Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2025—A 68-year-old male with a history of multiple myeloma was discovered to have a 3-cm carotid body mass on PET/CT. Surgery was consulted and determined that the lesion was not amenable to surgery. Radiology favored the lesion to be a paraganglioma, so plasma metanephrine and normetanephrine were tested and were negative. With paraganglioma as the working diagnosis, germline genetic testing was performed.
July 2025—We report the case of a 75-year-old female who initially presented with a 10-cm left pretibial mass on MRI. A biopsy revealed a high-grade spindle cell sarcoma with myofibroblastic differentiation. PET CT showed intense uptake in osseous lesions at the scapula, vertebral bodies, iliac bones, sacrum, and femoral head. A sacrum biopsy confirmed metastatic spindle cell sarcoma. The patient underwent chemotherapy and radiotherapy. A follow-up CT scan several months later revealed new liver and lung metastases, prompting molecular analysis of the sacrum specimen.
April 2025—Seen through the lens of metaphor, cancer staging is traffic control. Identify the biological crash, so to speak, and its severity; direct and redirect therapy; and try, ultimately, to unsnarl persistently risky crossings. That’s the sunny ideal. But efforts to improve traffic flow can also give rise to strong reactions, usually in words (if not a chorus of honking horns). Such is the case with the updated International Federation of Gynecology and Obstetrics staging system for endometrial cancer. FIGO 2023, by nearly all accounts, differs sharply from what had come before, incorporating molecular alterations, lymphovascular invasion, and tumor type and grade. Nearly two years later, it has yet to merge seamlessly into practice. “It definitely is controversial,” says Ekene Okoye, MD, associate professor of clinical pathology and genomic medicine, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College.
March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.
February 2025—Genetic profiling has long had proven winners in oncology: somatic testing of tumors, and germline testing for surveillance and to identify potentially affected relatives.
February 2025—Intracranial mesenchymal tumors (IMT) are extremely rare and account for only 0.3 percent of soft tissue tumors. Most frequently, mesenchymal tumors occur in subcutaneous tissue; they are rarely described in the central nervous system. In addition, these tumors typically occur in young adults,1 with a median patient age of 14 (range: four to 70).
January 2025—A study published last year found variability in the variants tested for in the commercial lab DPYD genotyping assays available at the time of the study, underscoring “the importance of comprehensive DPYD genotyping to accurately identify patients with DPD deficiency,” the authors said. Compromised dihydropyrimidine dehydrogenase deficiency raises a cancer patient’s risk of fluorouracil toxicity.
December 2024—On the heels of the publication of a joint consensus recommendation on DPYD genotyping, setting out what variants to test for, two experts who have studied the use of DPYD genotyping shed light in CAP TODAY interviews on its importance and its real-world impact.
December 2024—Case. A 73-year-old male with a clinical history of benign prostatic hypertrophy and pituitary macroadenoma status post-resection presented with lymphocytosis. This incidental lymphocytosis was noted within a preoperative CBC for a prostate procedure. At the time he was asymptomatic; medications included hydrocortisone, testosterone, and levothyroxine. Lymphadenopathy and splenomegaly were absent on physical examination. Complete blood counts showed WBC 25.8 × 109/L, hemoglobin 13.9 g/dL, hematocrit 42 percent, and platelets 134 × 109/L.
November 2024—Acute myeloid leukemia (AML) stands out as the most prevalent form of leukemia, constituting 80 percent of cases in adults and 15 to 20 percent in children. It arises from the clonal proliferation of genetically aberrant hematopoietic stem and progenitor cells, impeding normal hematopoiesis. AML is linked to a variable number of cytogenetic abnormalities, and the identification of these abnormalities holds crucial implications, given their association with an elevated risk of inherited AML.
